Inhibitory Effects of Myricetrin and Dihydromyricetin toward α-Glucosidase and Pancreatic Lipase with Molecular Docking Analyses and Their Interaction
Table 2
Interaction between myricetrin and dihydromyricetin on pancreatic lipase inhibition.
Ratio
Myricetrin
Dihydromyricetin
Pancreatic lipase inhibition (%)
CIa
Fab (%)
CI for Fa
Myricetrin
Dihydromyricetin
Tested concentration (μg/mL)
Calculated concentration (μg/mL)
1 : 1
50.0
50.0
28.33 ± 1.69
1.294
25.0
1.426
44.39
44.39
100.0
100.0
42.39 ± 2.24
1.188
50.0
1.044
128.35
128.35
150.0
150.0
52.76 ± 0.52
1.064
75.0
0.801
371.17
371.17
200.0
200.0
60.61 ± 2.82
0.962
85.0
0.700
686.34
686.34
250.0
250.0
68.32 ± 0.65
0.800
—
—
—
—
1 : 2
33.3
66.6
31.25 ± 2.41
1.034
25.0
1.247
26.52
53.03
66.7
133.4
47.02 ± 0.53
0.858
50.0
0.778
70.68
141.37
100.0
200.0
58.40 ± 0.63
0.711
75.0
0.511
188.41
376.83
133.3
266.6
65.73 ± 1.65
0.636
85.0
0.410
332.36
664.71
166.7
333.4
74.46 ± 0.41
0.469
—
—
—
—
2 : 1
66.7
33.3
29.50 ± 1.04
1.552
25.0
1.547
62.67
31.33
133.3
66.7
38.70 ± 1.34
1.447
50.0
1.388
207.40
103.70
200.0
100.0
46.78 ± 2.09
1.423
75.0
1.291
686.42
343.21
266.7
133.3
55.93 ± 1.14
1.352
85.0
1.253
1372.44
686.22
333.3
66.7
60.92 ± 1.23
1.331
—
—
—
—
aCI, combination index. CI ≤ 0.90, 0.90 < CI < 1.10, and CI ≥ 1.10 indicate synergistic, additive, and antagonistic effects, respectively; bFa, fraction affected by the combination dose of myricetrin and dihydromyricetin.
